Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person ERBB2 binds trastuzumab

Class:IdReaction:9652277
_displayNameERBB2 binds trastuzumab
_doReleaseTRUE
_timestamp2024-03-20 23:46:20
authored[InstanceEdit:9656339] Orlic-Milacic, Marija, 2019-07-31
compartment[Compartment:984] extracellular region
[Compartment:876] plasma membrane
created[InstanceEdit:9652267] Orlic-Milacic, Marija, 2019-06-28
disease[Disease:1500689] cancer
edited[InstanceEdit:9665760] Orlic-Milacic, Marija, 2019-11-01
input[Complex:1227970] ERBB2:ERBIN:HSP90:CDC37 [plasma membrane] [Homo sapiens]
[ProteinDrug:9634466] trastuzumab [extracellular region]
isChimericFALSE
literatureReference[LiteratureReference:9652354] p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
[LiteratureReference:9652351] Humanization of an anti-p185HER2 antibody for human cancer therapy
[LiteratureReference:9634297] The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
modified[InstanceEdit:9652372] Orlic-Milacic, Marija, 2019-06-28
[InstanceEdit:9665224] Orlic-Milacic, Marija, 2019-10-30
[InstanceEdit:9665326] Orlic-Milacic, Marija, 2019-10-30
[InstanceEdit:9666033] Orlic-Milacic, Marija, 2019-11-01
[InstanceEdit:9666039] Orlic-Milacic, Marija, 2019-11-01
[InstanceEdit:9666040] Orlic-Milacic, Marija, 2019-11-01
[InstanceEdit:9666041] Orlic-Milacic, Marija, 2019-11-01
[InstanceEdit:9666042] Orlic-Milacic, Marija, 2019-11-01
[InstanceEdit:9666684] Orlic-Milacic, Marija, 2019-11-05
[InstanceEdit:9667512] Orlic-Milacic, Marija, 2019-11-12
[InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
[InstanceEdit:9866055] Orlic-Milacic, Marija, 2024-03-20
nameERBB2 binds trastuzumab
output[Complex:9652349] ERBB2:trastuzumab:ERBIN:HSP90:CDC37 [plasma membrane] [Homo sapiens]
precedingEvent
releaseDate2019-12-10
reviewed[InstanceEdit:9662685] Kancha, Rama Krishna, 2019-09-16
reviewStatus[ReviewStatus:9821382] five stars
species[Species:48887] Homo sapiens
stableIdentifier[StableIdentifier:9652289] R-HSA-9652277.3
summation[Summation:9652268] ERBB2 signaling is inhibited by binding of ERBB2 to ERBB2-di...
(hasEvent)[Pathway:9634285] Constitutive Signaling by Overexpressed ERBB2 [Homo sapiens]
[Pathway:9652282] Drug-mediated inhibition of ERBB2 signaling [Homo sapiens]
(normalReaction)[FailedReaction:9665232] Resistant ERBB2 KD mutants do not bind trastuzumab [Homo sapiens]
[Reaction:9665405] ERBB2 ECD mutants bind trastuzumab [Homo sapiens]
[Reaction:9665696] ERBB2 TMD/JMD mutants bind trastuzumab [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by ERBB2 binds trastuzumab (9652277)
Follow Reactome